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Abstract
Context: Some cancer patients experience pain and fatigue whereas some others experience
only one of the two. Yet, it is not clear who experiences these unique patterns and why.
Objectives: This study aimed to identify subgroups of cancer patients with unique pain and
fatigue experiences in two different chemotherapy cycles, to examine how selected factors
influenced subgroup membership, and identify how subgroups differed in concurrently
measured functional-limitation outcome.
Methods: The sample included 276 patients with diverse cancer types from four U.S. sites.
To investigate subgroups, latent profile analyses were performed. Multinomial logistic
regression and one-way analyses of variance type analyses were conducted to examine the
influencing variables of subgroup membership and to examine differences among subgroups
in patient outcome.
Results: At both time points, the high-pain/high-fatigue and low-pain/low-fatigue subgroups
were found. The low-pain/high-fatigue subgroup was present only in the first chemotherapy
cycle. Pain and fatigue levels significantly differentiated subgroups at each time point (all
p < .05). Across two time points, experiencing higher depressed mood increased the risk to be
in the high-pain and high-fatigue subgroup (all p <.01). The high-pain and high-fatigue
subgroup had the most serious limitations in activities (all p < .01).
Conclusion: This study confirmed the existence of a unique symptom experience of pain and
fatigue. This pattern should be acknowledged for symptom assessment and management.
Key words: pain, fatigue, depressed mood, symptom cluster, symptom assessment, symptom
management, cancer.
Running Title: Unique Pain and Fatigue Experience

3

Introduction
Managing and assessing pain and fatigue, both prevalent in cancer patients, are major
priorities of oncology nursing research and practice.1 Of cancer patients, 70% suffer severe
pain, requiring immediate intervention.2 Fatigue, prevalent in 60 to 90% of patients,3 can
occur before diagnosis, during treatment, or years after treatment completion.4 Pain and
fatigue are key symptoms that lower the quality of life for individuals with cancer.2,5
Symptom-cluster researchers examine the co-occurring tendency of symptoms6 and
often report that pain and fatigue tend to form a symptom cluster either alone or with other
symptoms.7–9 However, several studies reported that pain and fatigue separately formed
clusters with other symptoms,10,11 suggesting that pain and fatigue occur together only in a
subgroup of cancer patients.
Recent studies examining subgroups with respect to unique symptom experience also
suggest that some cancer patients experience both pain and fatigue while some others
experience only one of the two.12–15 For instance, a cross-sectional study examined subgroups
with different symptom experience of pain, fatigue, depression, and sleep disturbance in a
mixed sample of cancer patients.13 This study found that 15% of the sample experienced high
intensity of all four symptoms; 15% experienced high intensity of pain and low intensity of
fatigue; 35% experienced high fatigue and low pain; and 35% experienced low levels of all
four symptoms. In another study, about 20% had only fatigue at four different time points
after diagnosis while 23–45% experienced fatigue with pain and/or insomnia across all time
points.15
It is unclear who experiences both or only one symptom and what leads to their
unique experience. This information helps delineate symptom management tailored to
patients with a particular symptom experience. Previous studies included other symptoms
such as insomnia, depressed mood, and cognitive disturbance, in addition to pain and fatigue,
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to create subgroups.12–14 The inclusion of multiple symptoms in analyses could have
hampered the examination of unique experiences concerning pain and fatigue as well as the
influence of factors on the two symptoms. For example, the subgroups may have been created
as a function of other symptoms, not of pain and fatigue only. Previous studies employed
cluster analysis of subjects.12,13 The weakness of cluster analysis includes subjectivity in
determining the number of subgroups; technical barriers in establishing replicability (i.e.,
reliability) of the final solution in the sample; and difficulty handling missing data.
The present study focused on only pain and fatigue in patients undergoing
chemotherapy (CTX) in two selected time points. Our previous analysis12 found the
subgroups with opposite directions of pain and fatigue in as discussed above and the present
study further examined those subgroups with different data set and different approach. The
treatment modality of CTX and radiation treatment both influence pain and fatigue
experience.12,15,16 The present study focused on symptom experience during CTX cycles. The
present study used latent profile analysis (LPA). LPA is a latent variable method and an
extension of latent class analysis for continuous indicators. Using LPA, psychologists and
sociologists examined subgroups with unique characteristics, such as substance-use
behaviors17 or phenotypes of eating disorders.18 In LPA, subgroups are determined by a latent
nominal variable and each subgroup has a unique profile of means and variances
corresponding to specified indicator variables (i.e., fatigue and pain intensity in this study).
The goals of LPA are often similar to those of cluster analysis.19 Yet, LPA solutions can be
replicated and are statistically robust in selecting numbers of subgroups, especially in
situations with non-normal distributions of indicators.20
Age, disease stage, cancer type, and comorbid conditions may be associated with
experiencing pain or fatigue.12,13,15,16 These variables were selected as influencing factors in
the present study. Figure 1 shows variables categorized by the theory of unpleasant
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symptoms,21 describing physiological, psychological, and situational factors. These factors
influence symptom experiences that can lower performance. Depressed mood has been
associated with fatigue and/or pain experience in many studies.12,13,22 In the present study,
depressed mood is categorized as a psychological factor rather than symptom per se, because
the present study planned to examine its influence on the pain and fatigue experience.
The purposes of this study were (a) to identify the subgroups of cancer patients with
unique experience of pain and fatigue at two CTX cycles, (b) to examine how selected factors
influenced subgroup membership, and (c) to examine how subgroups differed in concurrently
measured functional limitations.
Methods
Design
This study employed a secondary analysis. The data were originally collected as a
randomized clinical trial testing the effects of a cognitive behavioral intervention on fatigue
and sleep in cancer patients undergoing CTX.23 The experimental group received education
on energy-conservation strategies for fatigue and on sleep-enhancement strategies. The
control group received general information on nutrition and diet for the equivalent time. A
specially trained oncology nurse provided the intervention over the course of three interactive
telephone sessions during the second, third, and fourth week after the first CTX treatment.
Baseline data were collected at two time points: on Day 1 of the first CTX cycle
before receiving treatment (Time 0) and on Day 4 after the first CTX treatment (Time 1). The
follow-up time point (Time 2) was on Days 43–46 for patients on a weekly or 21-day
regimen, or on Days 57–60 for those on a 14-day or 28-day regimen. The follow-up time
point fell within 3 days of the most recent CTX treatment (after the 7th CTX for weekly
cycles, the 3rd CTX for 21-day cycles, the 5th CTX for 14-day cycles, and the 3rd CTX for
28-day cycles). Thus, Times 1 and 2 fell within 4 days of the most recent CTX. For the parent
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study, the criteria for the post-CTX time points was based on the time points found to have
maximal levels of symptoms after CTX (i.e., within 3 days of CTX).24,25 The present study
only used symptom data collected at Time 1 and Time 2, since this study focused only on
post-CTX symptom experience.
Settings and Sample
A convenience sample of oncology patients from four U.S. clinical sites were
collected from 2004 to 2007: University of Utah, University of Cincinnati, Christiana
Medical Center, and Fox Chase Cancer Center. Patients were at least 18 years of age;
initiated a new CTX regimen with at least one drug administered intravenously in a cyclic
manner; were diagnosed with lymphoma or breast, lung, colorectal, prostate, gynecologic,
bladder, or testicular cancer; had no treatment other than surgery for at least one month
before enrollment (concurrent radiation treatment allowed); and could read and understand
spoken English. Patients were excluded with marrow or stem-cell transplantation,
interleukins, interferon, or tumor-necrosis factor; chronic-fatigue disorder; sleep disorder;
psychiatric disorder; anemia or depression during the prior 3 weeks; communication
impairment; or enrollment in another psychoeducational intervention study.
A total of 276 patients composed the final sample for analyses in both the parent and
present study, consisting of an experimental group (n = 142) and a control group (n = 134).
No additional inclusion or exclusion criteria were applied. Because the experimental
intervention did not have a beneficial effect in reducing fatigue or sleep disturbance,23 both
groups were combined and analyzed as a unit in the present study. However, the effect of
experimental intervention on symptom experience at Time 2 was examined due to the
possibility that it could be associated with subgroup creation. Missing data on the latent class
indicators as well as covariates were handled by performing full information maximum
likelihood estimation from complete raw data and thus, all data from the 276 patients were

7

used to estimate a model for this study. Because the data had already been collected, the
sample size could not be changed. The findings were carefully interpreted according to the
size and nature of the sample.
Instruments
Pain intensity was measured by the intensity subscale of the Brief Pain Inventory.26 It
is composed of four items: the worst and least pain in the past 72 hours, average pain, and
pain at the present moment. The scale ranged from 1 = no pain to 10 = pain as bad as you can
imagine. Validity and reliability of this measure have been well established.26,27 Cronbach’s α
was 0.88 in the present sample.
The General Fatigue Scale (GFS), a fatigue measurement, was developed for the
clinical assessment of cancer-related fatigue.28 The GFS consists of seven items that measure
fatigue intensity, the level of distress caused by fatigue, and the impact of fatigue on daily
activities in the present day, the past 48 hours, or the past week. The scale ranged from 1 = no
fatigue to 10 = the greatest possible fatigue. Acceptable reliability and validity were
reported.28 In the present study, Cronbach’s α was 0.92.
The interference subscale of the Brief Pain Inventory measures interference with daily
life caused by pain for the past 72 hours. The parent study modified this subscale to measure
the interference due to symptoms, not specifically pain. The present study used this subscale
as a functional-limitation measure. The subscale contains seven items that measure
interference in general activity, life enjoyment, mood, relationships, sleep, walking, and work.
The scale ranges from 0 = did not interfere to 10 = completely interfered. Cronbach’s α was
0.91 in this sample.
Depressed mood was measured by the depression subscale from the Profile of Mood
States—Short Form.29 Validity and reliability were found to be acceptable in various
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populations29 The depression subscale consists of five items on a Likert-type scale where 0 =
not at all and 4 = extremely. Cronbach’s α was 0.90 in this sample.
Analysis
To identify subgroups, LPA with covariates was conducted at each data point,
estimated in Mplus v.6.12. Models were evaluated based on Akaike’s information criterion,
where smaller results were preferable;30 Bayesian information criterion, where a smaller
number was preferable;31 the Bootstrap Likelihood Ratio Test, where the number of
subgroups was tested against a smaller number of subgroups (p < 0.05 indicated that at least
the present number of subgroups exist in the data); an entropy value higher than 0.8, which
summarized the probability for the most likely latent class membership based on the
estimated model; the interpretability of classes;20 and the model’s convergence on a stable
solution. Where these criteria suggested different results, we subjectively assessed the
preponderance of evidence.
Interpretability was determined by distinguishability of subgroups in indicator
variables, nontrivial subgroups sizes, and subgroup meaningfulness. Model convergence was
examined through replication of maximum log-likelihood values across iterations, using
random starting values. Distributions of the indicator variables were examined for extreme
skewness and kurtosis. Pain had marked skewness and the model was estimated as if the
given variable were normally distributed beyond its measured scale by using the censored
command.
Subgroup-membership influencing factors were examined by multinominal logistic
regression predicting the latent nominal variable. Subgroup differences in functional
limitation were examined using the limitations measure as an “auxiliary variable” associated
with subgroup membership. This is analogous to a one–way analysis of variance (ANOVA)
based on the identified subgroups, but minimizes measurement error in the predictor by using
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subgroups as a latent variable. For missing data on subgroup indicators and covariates, we
performed full-information maximum-likelihood estimation from complete raw data; thus, all
data were used to estimate this study’s model. We obtained approvals from institutional
review boards.
Results
Sample Nature
Table 1 shows the demographic and clinical characteristics of the sample. Of note,
55% were recruited from the comprehensive cancer center at Fox Chase. Patients were
largely female, married, Caucasian, and had post-high school education. Half of the total
sample had breast cancer and early stage cancer (Stages I and II). Half received symptommanagement intervention designed in the parent study. Approximately 90% were treated with
CTX alone. The most frequent comorbid condition was hypertension (25%).
Subgroups of Cancer Patients with Unique Pain and Fatigue Experience
At Time 1, a model with three subgroups was selected based on the model selection
criteria (see Table 2). Table 3 summarizes the mean values of symptom intensity for each
subgroup. Pain was censored in the model estimation due to extreme skewness in distribution,
so it carries no clinical meaning, but rather shows the relative distribution across subgroups.
Subgroups were named based on pain and fatigue levels: high-pain/high-fatigue (HPHF;
41.2%), low-pain/high-fatigue (LPHF; 34.3%), and low-pain/low-fatigue subgroups (LPLF;
24.5%). According to the Wald tests, the subgroups differed from each other in both pain (all
p < .0001) and fatigue intensity (all p < .05; see Table 3).
The left panel of Figure 2 is a scatterplot of raw scores of respondents’ pain and
fatigue at Time 1. Although in analytic models, subgroup membership is latent—respondents
are never assigned to subgroups—points in the scatterplot are color coded by most likely
subgroup membership of each respondent, to show the approximate loci of each subgroup.
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Clinically, fatigue level was high in the HPHF subgroup; moderate in LPHF; and low in
LPLF. Pain level was moderate in HPHF; low in LPLF; and was not measurably present in
LPHF (see the left panel of Figure 2). Expected a posteriori classification based on the
selected LPA model would have correctly classified 92% of HPHF, 93% of LPHF, and 88%
of LPLF, corresponding to an entropy value of 0.80.
At Time 2, a model with two subgroups was selected: HPHF (36.5%) and the LPLF
(63.5%), graphically depicted in the right panel of Figure 2. Baseline model-testing statistics
indicated the possibility of the three subgroups (see Table 2), appearing to be similar to the
model at Time 1. However, the three-subgroup model was not selected due to the failure of
parameter estimation for several variables and due to the fact that maximum log-likelihood
value was not replicated, indicating convergence issue. Expected a posteriori classification
based on the selected LPA model would have correctly classified 89% of LPLF, and 84% of
HPHF, corresponding to an entropy value of 0.60. Although the low-entropy value was
concerning in model selection, this two-subgroup model was best replicated using the
maximum log likelihood value and was selected as the best model for Time 2. In the twosubgroup model, pain and fatigue levels significantly differed, according to the Wald tests
(all p < .001). HPHF had clinically moderate-to-high levels of pain and fatigue; LPLF had
clinically low levels of pain and fatigue (see the right panel of Figure 2).
Influencing Variables of Subgroup Memberships
Multinomial logistic regression analyses were conducted with 10 variables at Time 1
and 13 at Time 2 (see Table 4 for odds ratios). The three additional variables at Time 2 were
the time lapse from the first CTX (i.e., 43–46 days vs. 57–60 days), symptom management
intervention given by the parent study, and employment status. Employment status was
included only because this variable had an interaction with intervention in the parent study.
At Time 1, only depressed mood significantly influenced subgroup memberships. Patients
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with higher depressed mood were more likely to be in HPHF (odds = 57.89, p < .0001) or
LPHF (odds = 67.22, p < .0001), rather than LPLF.
At Time 2, depressed mood was the most important predictor, showing similar
tendencies as observed at Time 1. Patients with shorter time-lapses since first treatment (43–
46 days vs. 57–60 days) were less likely to be in HPHF (odd ratio = 0.14, p = .002). The
comorbid condition of hypertension and arthritis were included in the model because they
were the most prevalent. Patients with comorbid hypertension were more likely to be in
HPHF (odds ratio = 5.29, p = .01).
Subgroup Differences in Concurrently Measured Functional Limitation
Although the subgroup-mean levels of functional limitations (i.e., 5.36 vs. 4.33 vs.
1.49 at Time 1; 5.21 vs. 3.02 at Time 2) were moderate, statistically and clinically meaningful
differences existed between subgroups (see Table 5). Patients in HPHF had the most serious
functional limitations in both times (post hoc contrasts, all p < .01). At Time 1, functional
limitation in LPHF was higher than in LPLF, but lower than in HPHF (post hoc contrasts,
p < .01).
Discussion
LPA successfully identified subgroups with pain and fatigue that were replicable in a
given sampling distribution. Two subgroups with the same direction of pain and fatigue
intensity (HPHF and LPLF) are comparable to previous research findings on symptom
clusters: pain and fatigue formed a symptom cluster in some cancer patients. HPHF had the
most serious limitation in functional status. Thus, there is a clinical implication of a pain and
fatigue cluster, supporting cumulative effects of multiple symptoms on functioning.12–14,32,33
In addition, experiencing both pain and fatigue at a high intensity was independent of
most selected situational and physiological variables. A higher level of depressed mood
increased the risk to be HPHF, independent of other variables; depressed mood may be a
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sentinel to detect subgroup with high pain and fatigue. Depressed mood did not differentiate
between the two subgroups with high fatigue at Time 1, and is more closely associated with
fatigue than pain.
LPHF was found only at Time 1. The present study expected that patients with lower
hemoglobin would fall into LPHF, but this was not supported. The effect of hemoglobin was
inconclusive in this study due to limited variance and lack of control over the time lapsed
since blood sampling. As shown in Figure 2, symptom patterns appear to be similar over two
chemotherapy cycles with slightly more diversity at Time 2. However, LPHF was not
separable from LPLF, possibly due to the very small number of subjects experiencing the
LPHF pattern. Low pain and high fatigue experience may occur in patients with a particular
condition during CTX, and the condition should be further examined.
Previous studies reported 15–30% of participants with high pain and low fatigue.12,13
It was expected that this subgroup would be associated with surgery, because surgery-site
pain can occur without serious fatigue. However, the present study did not find this subgroup,
and furthermore, did not find the surgery experience to influence the symptom experience.
Considering that Time 1 was 4 days after the first CTX, both measurement time points
consisted of long periods after surgery for most patients in this study. In Kim et al.,12 surgery
experience predicted symptom experience only at the time point before CTX or radiation
treatment. Given et al.16 reported that the pain and fatigue experience was influenced only
when surgery was completed within 40 days. Surgery-related pain may occur without fatigue
within a short period after surgery, may be different from pain with fatigue, and should be
treated differently. Separating types of pain based on symptom experience may have
important implications for symptom management.
At Time 2, having a longer time-lapse from the first CTX and/or a comorbid
condition of hypertension predicted a high pain and high fatigue experience. Although the
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reason is not yet clear, the symptom experience could have been affected by medications for
hypertension, not hypertension per se, and by various events that occurred after the first CTX
(e.g., medications), not the time-lapse per se.
LPA was recently used to examine an association between cytokines and a symptom
cluster of pain, fatigue, sleep disturbance, and depression in a sample of cancer patients and
their family caregivers.34 Their findings are not comparable to the present study findings
because their subgroups were characterized by depression level, not by pain and fatigue level,
due to the nature of the sample: their sample included family caregivers who may not
experience serious pain and/or fatigue. Nonetheless, this particular study shows applicability
of LPA to investigate a possible mechanism of symptoms.
Limitations of this study include the use of many categorical variables, and crosssectional analysis of longitudinal data (i.e., separate analysis at each time point). Having too
many categorical variables hampered analyses due to zero variance in cells of multiple
categorical variables. Including more continuous variables, if possible, is recommended for
future study in particular working with a small sample size. Also, measurement time points
for influencing variables should be carefully selected to yield a clear conclusion. This study
sample included patients undergoing concurrent treatments of CTX and RT. However,
inclusion of those subjects would not influence on the study findings because the number is
too small (n=18) and the measurement time point was set to capture symptom experience
after CTX treatment. Using the longitudinal nature of the data, we are currently examined the
transition patterns of patients in pain and fatigue experience over two different time points.
Conclusion
This study provides evidence of the existence of subgroups with unique pain and
fatigue experiences in diverse cancer patients during CTX. Patients with both pain and
fatigue at higher intensities had the worst patient outcomes, and tended to experience more
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severe depressed mood. Clinicians need to pay special attention to this group of patients.
Opposing directions of pain and fatigue experience appeared to exist only at a specific time
point in the illness trajectory or with respect to patients with a particular cancer. Future
studies should investigate the assessment/management strategies targeting pain or fatigue
based on two main criteria: (a) the population where one can find a certain combination of
pain and fatigue, and (b) the possible reasons behind unique pain and fatigue-symptom
experience.
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Figure 1. Statistical model of the study
Influencing Factors of
Subgroup Membership

Situational variables

Indicators of Subgroups
which reflect characteristics of each subgroup

Pain

Fatigue

-Study site
-Employment status

Psychological variables
-Depressed mood
-Symptom management intervention
given by the parent study

Physiological Variables
-Age
-Type of cancer
-Disease stage
-Previous surgery
-Time lapse since the first CTX
-Comorbid condition: arthritis
-Comorbid condition:hypertension

Distal Outcome

Latent Nominal
Variable
which determines
subgroup
membership

which is influenced by
subgroup membership

-Level of functional
limitations

a

- Hemoglobin level before a time
point

Note. athe direct influence of the hemoglobin level on fatigue was allowed in this statistical model but its effect
was not tested.
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Table 1. Demographic/Clinical Characteristics of the Sample (N = 276)
Variables
Data collection site a

Site A

152 (55.1)

Site B

87 (31.5)

Others

37 (13.4)

Age (mean years ± SD)
Gender

Marital status

53.97 (±11.79)
Female

228 (82.6)

Male

48 (17.4)

Married

191 (69.2)

Single

81 (29.4)

Missing
Race

242 (87.7)

Non-Caucasian

30 (10.9)

70 (25.4)

Post-high school education

201 (72.8)

Cancer Type

Disease stage

Time lapse since the first CTX

5 (1.8)

Employed

150 (54.3)

Unemployed

122 (44.2)

Missing
Study Group b

4 (1.4)

High school or less

Missing
Employment status

4 (1.4)

Caucasian

Missing
Education

Number of patients (%)

4 (1.5)

Experimental group

142 (51.4)

Control group

134 (48.6)

Breast

152 (55.1)

Lung

47 (17.0)

Gynaecologic cancer

32 (11.6)

Lymphoma

23 (8.3)

Others

22 (8.0)

Stage 1

44 (15.9)

Stage 2

90 (32.6)

Stage 3

68 (24.6)

Stage 4

44 (15.9)

Not staged

30 (10.9)

43–46 vs.

159(57.6)

57–60 day

111(40.2)

Missing

6 (2.2)
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Variables
Surgery right before baseline

Number of patients (%)

Yes

198 (71.7)

No

75 (27.2)

Missing
Treatment modality during the study

Comorbid conditions

3 (1.1)

CTX only

250 (90.6)

Concurrent treatment with radiation treatment

18 (6.5)

Missing

8 (2.9)

Hypertension

69 (25.0)

Arthritis

28 (10.1 )

Hemoglobin at Time 1

12.92 (±1.6)

Hemoglobin at Time 2
a

11.75 (±1.6)
b

Note. Site A= Fox Chase Cancer Center, Site B= Utah. The primary study was a randomized clinical trial of
the effectiveness of a cognitive-behavioral intervention on fatigue and insomnia.
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Table 2. Comparisons of Models with Different Numbers of Subgroups at Each Time Point
No. of
classes

Likelihood
ratio G2

AIC

BIC (sample
size adjusted)

Bootstrapped
Likelihood
Ratio Test

Entropy

Time 1
2

6211.67

6127.86

6149.44

0.0000

.75

3

4537.80

6095.35

6123.67

0.01

.80

4

4537.80

6077.32

6112.38

0.6

.84

2

6646.84

6766.84

6793.81

0.000

.60

3

4165.36

6729.39

6764.46

0.000

.73

Time 2

2

Note. Likelihood Ratio G is – 2 times of loglikelihood value; Smaller Akaike’s information criterion (AIC) is
preferable; Smaller Bayesian information criterion (BIC) is preferable; p < 0.05 in Bootstrap Likelihood Ratio
Test indicates that at least the present number of classes exist in given data; A higher than 0.8 entropy value (i.e.,
the summary of the latent class probability for most likely latent class membership based on the estimated
model) is preferred.
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Table 3. Subgroups of Pain and Fatigue Experience at Each Time Point
(N = 276)
Subgroups at Time 1 Mean (SD)
HPHF
(n = 114, 41.2 %)

LPHF
(n = 90, 34.3 %)

Painb

3.91(1.65)

-16.36(7.56)

-0.07 (2.11)

Fatigue

7.08(1.52)

6.26(1.59)

3.30(0.96)

Symptoms

LPLF
(n = 68, 24.5 %)

Wald tests for
pairwise comparisonsa
(df = 1)
All p < .0001
All p < .05

Subgroups at Time 2 Mean (SD)
Symptoms

HPHF
(n = 101, 36.5%)

Painb

4.48 (1.52)

Fatigue

6.59(1.96)

a

LPLF
(n = 175, 63.5%)

b

Wald test
df = 1

-0.82 (2.99)

p < .0001

5.27 (1.78)

p < .001

Note: Bonferroni correction was done for multiple comparisons; Pain was censored and thus the value in this
table does not carry clinical meaning but it shows relative distribution across groups; HPHF = high pain and
high fatigue subgroup; LPLF = low pain and low fatigue subgroup; LPHF = low pain and high fatigue subgroup.
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Figure 2. Pain and Fatigue Subgroups Based on the Most Likely (expected a posteriori) Subgroup Membership of Each Respondent
Time 1

Time 2

Note: Intensity of each symptom is raw score and patients are classified based on the estimated model; The ranges of scores for fatigue and pain
were 1–10; Higher scores indicated more intense symptoms.
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Table 4. Odds Ratios and 95% Confidence Interval for Influencing Variables of Subgroup Membership
Time 1(n = 276)a
Comparison versus reference

HPHF vs. LPLF

LPHF vs. LPLF

Time 2 (n = 276)
HPHF vs. LPHF

HPHF vs. LPLF

Site A

6.57 (0.70, 61.33)

9.04 (0.86, 94.64)

0.73 (0.24, 2.22)

4.44 (0.50, 39.81)

Site B

7.69 (0.83, 71.14)

7.38 (0.71,76.12)

1.04 (0.30, 3.69)

3.09 (0.25, 38.57)

Age

0.77 (0.50, 1.16)

0.83 (0.53,1.29)

0.93 (0.69, 1.26)

0.96 (0.58, 1.58)

Cancer type (breast vs. others)
Disease stage
(stage I &II vs.III &IV)

1.94 (0.47,8.11)

4.78 (0.98, 23.24)

0.41 (0.17,0.94)

1.45 (0.37, 5.68)

0.96 (0.48, 1.91)

1.02 (0.48, 2.15)

0.94 (0.63, 1.41)

1.74 (0.96,3.16 )

Comorbid-arthritis

2.69 (0.59, 12.30)

1.94 (0.28, 13.37)

1.39 (0.44, 4.21)

3.30 (0.45, 24.01)

Comorbid- hypertension

0.72 (0.17,3.06)

0.64 (0.11,3.62)

1.13 (0.50, 2.60)

5.29 (1.49, 18.84)*

Hemoglobin level

0.92 (0.59,1.43)

0.93 (0.57,1.51)

0.99 (0.81, 1.21)

0.87 (0.61, 1.23)

Previous surgery (yes vs.no)

1.64 (0.40,6.61)

2.89 (0.61,13.70)

0.56 (0.24, 1.30)

0.72 (0.14, 3.47)

Depressed mood

57.89 (6.59, 509.09)***

67.22 (7.72, 585.13)***

0.86 (0.56, 1.33)

4.33 (1.82, 10.26)**

Time lapse since the first CTX (43–46 vs. 57–60 day)

0.14 (0.04, 0.47)**

b

1.45 (0.52, 4.02)

Symptom management (yes vs.no)
Employment statusc (employed vs. un-employed)
a

1.26 (0.40, 3.96)
b

Note. Bonferroni correction was done for multiple comparisons. At Time 1, the intervention was not given and thus this variable was not entered in the model at
Time 1. c Employment status interacted with the intervention effect on the secondary outcome of pain at Time 2 in the parent study and thus, this variable was
included in the model at Time 2 model estimation; HPHF = high pain and high fatigue subgroup; LPLF = low pain and low fatigue subgroup; LPHF = low pain and
high fatigue subgroup; *p < .05. **p < .01. ***p < .0001. An odds ratio >1 would mean that the higher-coded category (or higher values in a continuous variable)
was associated with the greater odds of being in a given subgroup as opposed to the reference subgroup. A p-value < .05 indicated that the effect of a variable was
significant after controlling for the rest of the variables in a model.
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Table 5. Differences in Functional Limitations by Subgroup at Each Time Point
(N = 276)
Time 1 Mean (SD)

Total
(n = 276)

HPHF
(n = 114, 41.2%)

LPHF
(n = 90, 34.3%))

LPLF
(n = 68, 24.5%)

Overall test
X2 (df=2) = 137.39
(p < .0001)

Functional limitations

5.36 (.22)

4.33 (.36)

1.49 (1.19 )

All p < .01 (df = 1)

Time 2 Mean (SD)

a

Total
(n = 276 )

HPHF
(n = 101, 36.5%)

LPLF
(n = 175, 63.5%)

Functional limitations

5.21(0.28)

3.02(0.19)

X2 (df=1) = 39.05
(p < .0001)

Bonferroni correction was performed for multiple comparisons; HPHF = high pain and high fatigue subgroup;
LPLF = low pain and low fatigue subgroup; LPHF = low pain and high fatigue subgroup.

a
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